JPMorgan Maintains 'Overweight' Rating on Eli Lilly and Company (LLY) With $1,100 PT

Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds.

On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target. This target boost follows the company’s Q2 results. While investor sentiment weakened over Phase 3 trial data for Orforglipron, which recorded an efficacy of 1-2 percentage points, roughly 2-4 pounds below expectations, the investment firm believes it has minimal long-term impact.

Furthermore, JPMorgan expressed confidence in Orforglipron, the company’s oral obesity drug candidate, believing that the drug’s prospects remain solid. Looking ahead, the investment firm backs its optimism with Eli Lilly and Company (NYSE:LLY)’s significant ramp-up, which is expected in the second half of 2026 and beyond. Thus, the company remains well-positioned to capture demand in the fast-growing obesity market.

Eli Lilly and Company (NYSE:LLY) specializes in treatments for diabetes, obesity, and other health conditions. It is included in our list of the Best Rebound Stocks To Buy.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks.

Disclosure: None.